 |
Vol.57 No.2 contents | Japanese/English |
 | Full Text of PDF (1482K) Article in Japanese |
- Invited Review Article -
The Position of Nivolumab
Hideaki Shiraishi1, Yasushi Goto11Department of Thoracic Oncology, National Cancer Center Hospital, Japan
The approval of nivolumab and pembrolizumab for advanced non-small cell lung cancer has allowed some patients to receive benefits such as prolonged overall survival and a long-term response with relatively mild adverse events. Meanwhile, there are patients who suffer from various disadvantages due to inappropriate patient selection, errors in evaluating treatment effects and high drug prices. We therefore need to evaluate the evidence and issues associated with nivolumab in order to better prepare any associated problems that need to be overcome in the future.
key words: Nivolumab, Immune checkpoint inhibitor, Financial toxicity, Predictive marker, Evaluation of the effectiveness
JJLC 57 (2): 81-87, 2017
